SEGMENTED INFORMATION

9 Months Ended

Sep. 30, 2023

SEGMENTED INFORMATION

SEGMENTED INFORMATION

NOTE 11 – SEGMENTED INFORMATION

At September 30, 2023, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia (formerly known as Bionexus Gene Lab Sdn. Bhd.) and Chemrex.

	BioNexus Gene Lab Corp., a Wyoming company
100% owned		100% owned
MRNA Scientific Sdn. Bhd. (formerly “Bionexus Gene Lab Sdn. Bhd.”), a Malaysian company		Chemrex Corporation Sdn. Bhd., a Malaysian company

At September 30, 2023, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia and Chemrex.

For the nine months ended September 30, 2023, segmented (unaudited) revenue and net profit/(loss) (Currency expressed in United States Dollars (“US$”) are as follows:

	MRNA Scientific Malaysia			Chemrex			BGLC			Total
	Nine months ended September 30, 2023
REVENUE	$	28,468		$	7,469,271		$	-		$	7,497,739
COST OF REVENUE		(14,849	)		(6,419,947	)		-			(6,434,796	)
GROSS PROFIT		13,619			1,049,324			-			1,062,943
OTHER INCOME		3,922			507,870			-			511,792
OPERATING EXPENSES
General and administrative		(170,590	)		(2,348,127	)		(1,907,360	)		(4,426,077	)
LOSS FROM OPERATIONS		(153,049	)		(790,933	)		(1,907,360	)		(2,851,342	)
FINANCE COSTS		(2,952	)		(6,794	)		-			(9,746	)
LOSS BEFORE TAX		(156,001	)		(797,727	)		(1,907,360	)		(2,861,088	)
Tax expense		-			(76,418	)		-			(76,418	)
NET LOSS	$	(156,001	)	$	(874,145	)	$	(1,907,360	)	$	(2,937,506	)

	MRNA Scientific Malaysia			Chemrex			BGLC			Total
	Nine months ended September 30, 2022
REVENUE	$	39,409		$	8,049,723		$	-		$	8,089,132
COST OF REVENUE		(19,173	)		(7,150,156	)		-			(7,169,329	)
GROSS PROFIT		20,236			899,567			-			919,803
OTHER INCOME		6,617			146,720			3			153,340
OPERATING EXPENSES
General and administrative		(157,686	)		(906,698	)		(177,247	)		(1,241,631	)
(LOSS)/PROFIT FROM OPERATIONS		(130,833	)		139,589			(177,244	)		(168,488	)
FINANCE COSTS		(2,196	)		(5,521	)		-			(7,717	)
(LOSS)/PROFIT BEFORE TAX		(133,029	)		134,068			(177,244	)		(176,205	)
Tax expense		-			(22,792	)		-			(22,792	)
(LOSS)/PROFIT AFTER TAX	$	(133,029	)	$	111,276		$	(177,244	)	$	(198,997	)

20

BIONEXUS GENE LAB CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

(Currency expressed in United States Dollars (“US$”))

(Unaudited)

	As of September 30, 2023 and December 31, 2022
	Total Assets				Total Liabilities
	2023		2022		2023		2022
BGLC & MRNA Scientific	$	5,002,908	$	677,477	$	176,805	$	108,390
Chemrex		6,462,614		8,062,685		1,601,002		1,966,759
TOTAL		11,465,522		8,740,162		1,777,807		2,075,149